Patents Assigned to Universite Claude Bernard Lyon 1
-
Patent number: 11845830Abstract: The present invention relates to a method for producing a composition comprising at least one polyurethane with NCO end groups, and at least one catalyst B selected from among tertiary amines, said method comprising the following steps: a) production of a polyurethane with NCO end groups, comprising a step of polyaddition of a polyol composition and a polyisocyanate composition, in the presence of at least one catalyst A selected from the group consisting of—organo-metallic catalysts excluding tin-based catalysts, —tertiary amines, and—mixtures of same; and b) the addition of at least one catalyst B, selected from among tertiary amines, to the polyurethane with NCO end groups obtained in step a).Type: GrantFiled: December 19, 2018Date of Patent: December 19, 2023Assignees: BOSTIK SA, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CPE LYON FORMATION CONTINUE ET RECHERCHE—CPE LYON FCRInventors: Federico Sanz, Guillaume Michaud, Frédéric Simon, Jean Raynaud, Vincent Monteil, Lionel Bosco
-
Patent number: 11845944Abstract: The disclosure relates to a promoter induced by fungal rust. More specifically, the promoter is induced by the pathogen Phakopsora pachyrhizi, i.e. the Asian Soybean Rust. The disclosure further provides for recombinant genes comprising the promoter and methods of producing a transgenic plant that involves introducing or providing the recombinant gene to plant cells to create transgenic plant cells, and regenerating transgenic plants from the transgenic cells.Type: GrantFiled: May 11, 2018Date of Patent: December 19, 2023Assignees: Centre National De La Recherche Scientifique, Institut National des Sciences Appliquees de Lyon, Universite Claude Bernard Lyon 1, BASF Agricultural Solutions Seed US LLCInventors: Lisa Cabre, Sophie Ducerf, Stephane Peyrard, Catherine Sirven, Bernard Pelissier
-
Publication number: 20230381185Abstract: Described herein is a novel nanocomposite for oral administration for treatment of gastrointestinal disease, e.g., IBD, or injury. The nanocomposite contains nanoemulsion particles (NEs), loaded with an active therapeutic agent, that are then combined with a second component containing a self-assembling peptide(s) (SAP) or peptidomimetic(s) (optionally, the second component is in a powder form). Upon administration, when hydrated at slightly acidic or near-neutral pH, the system self-assembles into a hydrogel matrix enveloping NEs, which then adheres to, and more efficiently delivers, the active agent to the intestinal tract of a treated subject. The nanocomposite can be administered in a capsule dosage form that forms a depot in the stomach or post-stomach.Type: ApplicationFiled: May 12, 2023Publication date: November 30, 2023Applicants: 3-D Matrix, Ltd., UNIVERSITE CLAUDE BERNARD LYON 1, Hôpital Lyon SudInventors: Giovanna Lollo, Marie Reveiller Buffier, Sharanya Sankar, David Kryza, Annalisa Rosso, Vanentina Andretto, Stephane Nancey, Gilles Boschetti
-
Patent number: 11823881Abstract: An elementary particle detector including first sensors able to measure an amount of electric charge on electrodes of a readout plate and a processing unit able to determine the location of an avalanche of secondary electrons from the amount of electric charge measured by the first sensors and from the known location of the electrodes. The detector also includes at least one second sensor, each second sensor being able to measure an electrical signal produced by the secondary electrons when they pass through a conductive gate. The processing unit is additionally able to establish an arrival time of the elementary particle from a time at which the electrical signal is measured by the second sensor.Type: GrantFiled: January 16, 2020Date of Patent: November 21, 2023Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor: Imad Laktineh
-
Publication number: 20230364306Abstract: Three-dimensional body implants including a hydrogel, which includes cross-linked alginate and gelatin, and in particular breast implants. The hydrogel of the implants has a mechanical strength of 1 kPa to 1000 kPa, and the hydrogel of the implants may further include fibrinogen. The implants include a porous zone, and the implants are acellular, i.e., free of cells during their manufacture.Type: ApplicationFiled: June 24, 2022Publication date: November 16, 2023Applicants: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE CENTRALE DE NANTES, ECOLE SUP CHIMIE PHYS ELECTRONIQ LYON, HEALSHAPEInventors: Christophe MARQUETTE, Audrey CHERBLANC, Morgan DOS SANTOS, Luciano VIDAL, Emma PETIOT, Laura CHASTAGNIER, Amélie THEPOT, Baptiste GODET
-
Publication number: 20230360912Abstract: A method for producing nanostructures having a metal oxide shell, carried by a top face of a substrate whose greatest dimension is greater than or equal to 100 mm by MOCVD metalorganic chemical vapour deposition, including successive steps carried out in a reactor configured for MOCVD deposition of nucleation and growth. The nucleation step includes forming non-contiguous metal nuclei by depositing a metal by MOCVD using a metalorganic precursor on the top face of the substrate and oxidising the metal of the metal nuclei, to form oxidised nuclei and ensure stabilisation of the nuclei. The growth step includes depositing a metal by MOCVD using the metalorganic precursor, to form non-contiguous nanostructures by growth of the oxidised nanostructures, and oxidising the deposited metal of the nanostructures formed in the nucleation to form oxidised nanostructures.Type: ApplicationFiled: November 26, 2020Publication date: November 9, 2023Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE GRENOBLE ALPES, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, ECOLE CENTRALE DE LYON, ECOLE SUPERIEURE CHIMIE PHYSIQUE ELECTRONIQUE LYONInventors: Pierre-Vincent GUENERY, Thierry BARON, Jeremy MOEYAERT
-
Publication number: 20230348934Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: ApplicationFiled: March 6, 2023Publication date: November 2, 2023Applicants: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Santé et de la Recherche Medicale (INSERM), Centre National de la Recherche ScientifiqueInventors: Caroline COSTA FEJOZ, Els Verhoeyen, François-Loîc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Patent number: 11801400Abstract: A therapy apparatus for treating tissue by emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve with centres of curvature; centres of curvature asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry or from at least one of the axis of symmetry and at different depths taken according to the axis of symmetry; the individual axes intersecting between the focal zones and the creation surface or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone which is off-axis relative to the plane of symmetry or to the axis of symmetry; the sectors of this creation surface creating energy deposit zones with profiles corresponding to the focal coverage zones.Type: GrantFiled: April 1, 2021Date of Patent: October 31, 2023Assignees: EDAP TMS FRANCE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDECALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE LEON BERARDInventors: Marine Sanchez, David Melo De Lima, Jérémy Vincenot
-
Patent number: 11795465Abstract: The present invention relates to new transcriptional promoters that are functional during meiosis. It thus provides new tools, methods and compositions for the expression of proteins during meiosis in a eukaryotic cell, and more particularly in a plant cell.Type: GrantFiled: May 23, 2019Date of Patent: October 24, 2023Assignees: MEIOGENIX, INTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE DE LYONInventors: Giacomo Bastianelli, Alain Nicolas, Peter Rogowsky
-
Publication number: 20230323306Abstract: A jammed gel bioink comprises a self-assembling peptide solution comprising a self-assembling peptide, and a cell solution comprising living cells and a cell culture medium. The self-assembling peptide solution is extruded to form an object, and then the cell solution is injected into the object. Useful methods of making the jammed gel bioink are also disclosed.Type: ApplicationFiled: April 5, 2023Publication date: October 12, 2023Applicants: 3-D Matrix, Ltd., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE CLAUDE BERNARD LYON 1 (UCBL1), L’ECOLE SUPERIEURE DE CHIMIE, PHYSIQUE, ELECTRONIQUE DE LYON (CPE Lyon)Inventors: Christophe A. Marquette, Marie Reveiller Buffier, Marika G. Rioult, Eun Seok Gil
-
Publication number: 20230323305Abstract: A bioink comprises a cell solution comprising living cells and a cell culture medium, and a self-assembling peptide solution comprising a self-assembling peptide. The bioink is formed by mixing and extruding the cell solution and the self-assembling peptide solution together, and the bioink can be continuously extruded from the mixer after mixing. Useful methods of making bioinks and are also disclosed.Type: ApplicationFiled: April 5, 2023Publication date: October 12, 2023Applicants: 3-D Matrix, Ltd., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE CLAUDE BERNARD LYON 1 (UCBL1), L’ECOLE SUPERIEURE DE CHIMIE, PHYSIQUE, ELECTRONIQUE DE LYON (CPE Lyon)Inventors: Christophe A. Marquette, Marie Reveiller Buffier, Marika G. Rioult, Eun Seok Gil
-
Patent number: 11769894Abstract: The invention relates to a biocell (1) with a biofuel reservoir intended to be brought into contact with a liquid medium and with a fluid medium comprising an oxidant. Said biocell comprises a first electrochemical cell having: an anode (5) comprising a first enzyme capable of catalyzing the oxidation of the biofuel; —a cathode (7) comprising a second enzyme capable of catalyzing the reduction of the oxidant; and —a separating and porous membrane (3), electrically insulating, and permeable to said liquid medium, placed between the anode (5) and the cathode (7). Said biocell (1) being characterized in that it comprises a means for storing the biofuel (3) and for providing the liquid medium to the anode (5), said means comprising a hydrophilic porous material in contact with said anode (5)) and having a basis weight of 500 to 900 g/m2.Type: GrantFiled: May 31, 2019Date of Patent: September 26, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ GRENOBLE ALPES, ECOLE CENTRALE DE LYON, UNIVERSITÉ CLAUDE BERNARD LYON 1Inventors: Alan Le Goff, Yannig Nedellec, Caroline Abreu, Serge Cosnier, Michaël Holzinger
-
Publication number: 20230278983Abstract: The present invention relates to indole derivatives of formula (I?) as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.Type: ApplicationFiled: July 6, 2021Publication date: September 7, 2023Applicants: Universite Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Madicale, Centre National de la Recherche Scientifique, Ecole Normale Superieure de Lyon, Commissariat à l'Energie Atomique et aux Energies AlternativesS, Centre Leon BerardInventors: Alexandre Bancet, Claude Cochet, Odile Filhol-Cochet, Isabelle Krimm, Thierry Lomberget, Marc Le Borgne
-
Patent number: 11693003Abstract: The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.Type: GrantFiled: April 24, 2017Date of Patent: July 4, 2023Assignees: Hospices Civil de Lyon, Universite Claude Bernard Lyon 1, Eurobio ScientificInventors: Pierre Miossec, Ndieme Thiam, Jean-Jacques Pin
-
Patent number: 11649253Abstract: The present technology relates to luminescent lanthanide complexes comprising a chelating agent, formed of a macrocycle or ligand, complexing a lanthanide ion Ln3+ selected from terbium and dysprosium, the chelating agent comprising at least one group of the structure (B) below; and a process for detecting a biomolecule using said lanthanide complex comprising coupling a luminescent lanthanide complex of the present technology having a reactive group with said biomolecule.Type: GrantFiled: July 5, 2018Date of Patent: May 16, 2023Assignees: ECOLE NORMALE SUPERIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Amandine Roux, Anh-Thy Bui, Olivier Maury, Chantal Andraud
-
Patent number: 11629203Abstract: A photopolymerizable composition comprises at least a polymerizable resin, a photosensitizer, an annihilator, and a photoinitiator. The photosensitizer is formulated to absorb an excitation light signal received in a first range of wavelengths. The annihilator is formulated to emit a light signal in a second range of wavelengths different from the first. During the absorption of light by the photosensitizer in the first range of wavelengths, the annihilator emits a light signal in the second range, a photon energy of the emitted light signal being greater than a photon energy of the light signal received by the photosensitizer. The annihilator is also formulated to implement an energy transfer mechanism to excite the photoinitiator for polymerization of the resin. The excited photoinitiator is formulated to generate at least one polymerizable initiator to cause the polymerization reaction. Related methods, such as three-dimensional printing methods, and materials are also disclosed.Type: GrantFiled: July 31, 2018Date of Patent: April 18, 2023Assignees: ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Patrice Baldeck, Akos Banyasz
-
Patent number: 11623950Abstract: The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence comprising successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig? in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig?, said intronic sequence comprising an internal 5? splice site enabling the splicing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3? terminal exon of said gene; B4) a sequence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobuType: GrantFiled: July 8, 2016Date of Patent: April 11, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE DE LYONInventors: Floriane Fusil, Els Verhoeyen, Thierry Defrance, François-Loïc Cosset
-
Patent number: 11608509Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: GrantFiled: April 20, 2017Date of Patent: March 21, 2023Assignees: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Caroline Costa Fejoz, Els Verhoeyen, François-Loïc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Patent number: 11602327Abstract: Method and system for localizing a region of interest in a medium in which cavitation occurs. Method for localizing a region of interest (R) in a medium (M) in which cavitation occurs, the method comprising the steps consisting in: producing cavitation in the region of interest (R), the cavitation generating an acoustic signal, at each of at least three separate positions, detecting a cavitation signal representative of the acoustic signal of the cavitation, for at least two pairs of cavitation signals, determining a delay between the cavitation signals of each pair of cavitation signals, calculating a localization of the region of interest (R) based on the delays and the positions.Type: GrantFiled: August 28, 2017Date of Patent: March 14, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, TOHOKU UNIVERSITYInventors: Cyril Lafon, Jean-Louis Mestas, Maxime Lafond, Shin-Ichiro Umemura
-
Patent number: 11590225Abstract: Provided herein are nanoparticle compositions (e.g., nanoparticle compositions comprising high atomic number ions) that are useful for imaging diseases in a subject as well as radiosensitizing a disease in a subject (e.g., radiosensitizing a cancer in the subject). Methods of imaging a subject, methods of treating cancer, and processes of preparing the nanoparticle compositions are also provided.Type: GrantFiled: December 8, 2017Date of Patent: February 28, 2023Assignees: The Brigham and Women's Hospital, Inc., NH TherAguix, Université Claude Bernard Lyon 1, Centre National de la Recherche ScientifiqueInventors: Ross Berbeco, Eloise Thomas, Francois Lux, Olivier Tillement, Alexandre Detappe, Geraldine Le Duc